Physician profile
Fred Eugene Notarnicola
NPI 1235239799
$10,574.95
in general payments reported to CMS, 2019-2025
50 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $782 · 2021: $1,705 · 2022: $1,021 · 2023: $1,070 · 2024: $1,740 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,316.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,874.74 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,147.21 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $904.88 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $878.16 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $772.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $619.53 | 2025 | Caplyta |
| Pfizer INC. | $465.27 | 2019-2025 | |
| Lilly USA, LLC | $450.84 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $344.57 | 2025 | Auvelity, Symbravo |
| Allergan, INC. | $304.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.17 | 2023-2024 | Cyltezo |
| Otsuka America Pharmaceutical, INC. | $221.95 | 2022-2025 | Rexulti |
| Medtronic, INC. | $207.77 | 2024 | Linq II |
| Teva Pharmaceuticals USA, INC. | $173.24 | 2019-2025 | Austedo Xr |
| Sk Life Science, INC. | $163.62 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Notarnicola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.